equicenta® CTM is an investigational biologic derived from equine umbilical cord tissue. It has been evaluated by intra-articular and intralesional injection in two peer-reviewed publications.
Our peer-reviewed trial in Frontiers in Veterinary Science is live, the largest controlled trial of its kind in equine regenerative medicine.
To characterize the protein composition and cytokine profile of a cryopreserved, microparticulate equine umbilical cord (UC)…
Read More
A summary of the article: “Cryopreserved equine umbilical cord tissue allograft characterization and…”
Read More
This summary describes three in vivo studies of a cryopreserved equine umbilical cord allograft…
Read More
Lot-to-lot consistency analysis demonstrating <5% batch-to-batch variation across donors and what that means for clinical reliability…
Read MoreTwo peer-reviewed publications describe the characterization, biocompatibility, and clinical evaluation of equicenta® CTM. Review the published studies, or request scientific information from our team.
Questions about the data? Request scientific info
BMC Medicine · 2025
Frontiers in Veterinary Science · 2026
Source: Bertone AL, et al. BMC Medicine 2025; Front. Vet. Sci. 2026.
Now Published
In a published, open-label controlled trial (Bertone et al., 2026), a single injection of equicenta® CTM was associated with 2.72:1 odds of returning to prior performance. Injection reactions were reported after 3.4% of equicenta® CTM injections and 10.5% of standard-of-care injections.
Study limitations: open-label design; heterogeneous, clinician-selected comparator; funded by Equine Performance Labs.
For use by or on the order of a licensed veterinarian. Not for use in humans.
By submitting, you agree to receive occasional science and product updates from Equine Performance Labs. Unsubscribe anytime.
